From: Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
Switch patients with ≥ 5 points reduction
Total (N = 75)
38 (50.7%)
EM (N = 34)
22 (64.7%)
CM (N = 41)
16 (39.0%)